News Center
Details
Integrate resources across the pharmaceutical industry, commerce, and trade sectors to enhance the quality of the company’s international business development.
Release time:
2022-07-01 11:31
Source:
In recent years, Renfu Pharmaceutical, a leading player in the anesthesia and sedation sector, has continuously enhanced and strengthened its core competitiveness through “focus, innovation, and internationalization.” Strengthen the integration of pharmaceutical, commercial, and industrial resources overseas among subsidiaries such as Epic Pharma, Yichang Renfu, Wuhan Puke, U.S. Puke, and Renfulikang. Following the approach of “expanding dosage forms, expanding markets, and upgrading products,” gradually transition from generic ANDA products to high-end ANDA products and innovative drugs, continuously enhancing the quality of the company’s international business development.
| Customer Name |
Project Varieties |
Registration Classification for Filing |
Stage |
| Epic Pharma, LLC |
Gabapentin Capsules |
ANDA |
FDA Approved |
| Gabapentin Capsules |
4 Class |
NMPA Listing Registration Filing |
|
| Wuhan Renfu Pharmaceutical Co., Ltd. |
Solifenacin Succinate Tablets |
4 Class |
NMPA Approved for market launch and commercial production |
| Abidol Hydrochloride Tablets |
3 Class |
Listing Registration Filing |
|
| Yichang Renfu Pharmaceutical Co., Ltd. |
Oseltamivir Phosphate Capsules |
4 Class |
Listing Registration Filing |
| Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd. |
BTK486 Capsule |
1.1 Class |
Phase I Clinical Trial of a New Drug |
| Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd. |
ALK-089 Capsule |
1 Class |
Phase I Clinical Trial of a New Drug |
| Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd. |
HWH340 piece |
1.1 Class |
Phase I and Phase II Clinical Trials of New Drugs |
| Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd. |
HWH021199 piece |
1.1 Class |
Phase I Clinical Trial of a New Drug |
| Chengdu Zeling Biopharmaceutical Technology Co., Ltd. |
FM piece |
1 Class |
Phase I Clinical Trial of a New Drug |
| Suzhou Runxin Biotechnology Co., Ltd. |
RX518 Capsule |
1 Class |
Phase I Clinical Trial of a New Drug |
| Chengdu Zeling Biopharmaceutical Technology Co., Ltd. |
ZL-82 piece |
1 Class |
Phase I Clinical Trial of a New Drug |
| Hubei Provincial Institute of Pharmaceutical Industry Research Co., Ltd. |
F573 for Injection |
1 Class |
Phase I Clinical Trial of a New Drug |
| Chengdu Zeling Biopharmaceutical Technology Co., Ltd. |
PM for Injection |
1 Class |
Phase I and Phase II Clinical Trials of New Drugs |
| Aitiya (Shanghai) Pharmaceutical Co., Ltd. |
UP-818-CC Injection solution |
1 Class |
1 Phase I and Phase II Clinical Trials for New Drugs |
| Sandia Pharmaceutical Technology (Shanghai) Co., Ltd. |
Iododeoxyuridine for Injection |
1 Class |
I Phase I clinical |
| Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd. |
Peramivir Sodium Injection |
3 Class |
Prepare for listing registration filing |
Renfu is poised to make a big splash! Twenty Class 1 new drugs and 18 improved new drugs are set to hit the market soon, with the launch of a blockbuster first generic poised to ignite a trillion-dollar market. https://mp.weixin.qq.com/s/IZ3H2RzPiB3t8M5JUBNBlA
Trending News
Corporate culture
Make drug launches safer and faster, and ensure the tree of life remains evergreen.
Learn moreContact Us
Business customer service
-
Telephone：:+86-027-86506632
Human Resources Department
Address: No.98 shendun 2nd Road, Donghu New Technology Development Zone, Wuhan
Official wechat
Copyright: Wuhan humanwell likang pharmaceutical co.,ltd